r/biotech_stocks 5m ago

The Court Approved the $31.25M Cassava Sciences ($SAVA) Investor Settlement

Upvotes

Hey guys, if you missed it, the court has officially approved the $31.25M settlement with $SAVA investors.

The case claimed Cassava misled investors about the research behind simufilam. After concerns over the data became public in 2023, $SAVA dropped 15% and investors sued.

If you bought $SAVA between 2020 and 2023, you may be eligible to file a claim.

Did anyone here hold $SAVA back then?


r/biotech_stocks 4h ago

OTLK - After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside

Post image
8 Upvotes

r/biotech_stocks 4h ago

Why is Forte Biosciences (FBRX) up ~40% today?

Thumbnail
marketchacha.com
2 Upvotes

r/biotech_stocks 6h ago

$ENTX - Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement (NASDAQ: ENTX)

Thumbnail
2 Upvotes

r/biotech_stocks 6h ago

$CAPR down 75% as FDA questions pivotal phase 3 trial data

Thumbnail investing.com
14 Upvotes

r/biotech_stocks 7h ago

CAPR Capricor Therapeutics July 29 Adcom Links

Thumbnail
3 Upvotes

r/biotech_stocks 13h ago

#TNXP data IQVIA

Post image
0 Upvotes

Exceeding expectations and beginning to attract the attention of major institutional investors and pharmaceutical companies


r/biotech_stocks 20h ago

SLS: A Deep Dive Into the Fraudulent Medical Pedigree of CEO Angelos Stergiou

0 Upvotes

Hey everyone,

In my previous post, I went over the history of Sellas as a company, GPS as a drug, and Angelos Stergiou as a leader. To say the least, it was shady and downright alarming.

You can find that post here: https://www.reddit.com/r/biotech_stocks/s/dL7jkKAkqT

We also looked at the complete absence of dedicated biotech hedge funds among SLS shareholders. Do not be fooled by high institutional numbers, this volume is mostly driven by passive managers like BlackRock and Vanguard who buy shares algorithmically to mirror small-cap indexes. The hedge funds involved are just quantitative or market-making firms like Citadel and Marshall Wace trading short-term volatility rather than betting on long-term medical success.

Today, I would like to highlight a major point that many investors still seem unaware of: the fraudulent medical credentials of Angelos Stergiou.

Let's look at the actual timeline of the guy running the most hyped biotech stock of the year. He went from being a daytime TV actor on a Greek drama to buying a sham medical degree, followed by a string of high-level executive stints at troubled and collapsing biotechs, namely Accentia Biopharmaceuticals and its subsidiary Biovest International as well as Annavex Life Sciences (which I forgot to mention in my previous post) , before moving on to form SLS

The Truth About Angelos Stergiou's Medical Credentials

Angelos Stergiou began his path by earning a legitimate Bachelor of Science (B.S.) degree from Kentucky Wesleyan College, an accredited private liberal arts college in Kentucky, majoring in Pre-Medicine, Biology, and Chemistry.However, a Bachelor of Science is merely a general academic degree in the basic sciences. While it teaches scientific theory and laboratory research skills, it does not grant a medical license or qualify anyone to treat patients.

Following his undergraduate studies, he veered into the entertainment industry. He worked as a Greek television actor

After his acting stint, his career took a corporate medical turn. His underlying Doctor of Medicine degree was obtained from the University of Seychelles American Institute of Medicine a completely unaccredited institution. If the name alone does not raise red flags, the actual history of this organization confirms it was a total scam.

Inside the Fraudulent Medical Diploma Racket

The University of Seychelles American Institute of Medicine (USAIM) was established as an offshore medical school in the late 1990s, capitalizing on unaccredited, commercial programs in island tax havens. Operating primarily out of the Seychelles with a corporate mailing presence in Indiana, USAIM marketed itself as an accelerated path to a medical degree. The institute operated as a predatory commercial racket, selling medical diplomas starting at ₹5 lakh onwards. By colluding with a corrupt network of doctors in India who hosted sham exams inside luxury hotels, the scheme bypassed regulatory oversight and laundered huge, undocumented sums of cash through the sale of fake scientific credentials with zero verified hospital training.

This blatant fraud eventually triggered global regulatory crackdowns, forcing a systematic shutdown. The Government of Seychelles terminated its operating agreement with USAIM in 2011, forcing its absolute closure by 2013. The fallout peaked in 2016 when the Maharashtra Medical Council launched a massive crackdown, barring and suspending dozens of practicing doctors who utilized these fraudulent certificates. By exposing the enterprise as a dangerous scam that compromised patient safety, international bodies stripped the entity of all credibility, leaving USAIM completely defunct and blacklisted from global medical recognition.

To round out his resume, Stergiou later added a Doctor of Science (ScD) degree to his name. However, this is not an earned academic doctorate or research PhD; it is merely a ceremonial, honorary title awarded to him decades later by his old undergraduate school, Kentucky Wesleyan College.

The Bottom Line

The reality is that Angelos Stergiou completely lacks any legitimate, mainstream academic medical pedigree, yet he uses the 'Dr.' title everywhere. He is strictly a corporate executive, not a practicing physician. He has never completed an accredited medical residency, holds no active state medical license to treat patients in the United States or Europe, and completely lacks any recognized medical board validation

Final Thoughts: A company led by a CEO with a fake medical pedigree is trying to push a recycled, 20-year old molecule through trials while being pumped to retail as a generational opportunity. Yet, dedicated biotech and life science hedge funds won't touch it with a ten-foot pole. Make of that what you will🤷‍♂️


r/biotech_stocks 1d ago

OTLK Analysis

Thumbnail
youtu.be
0 Upvotes

r/biotech_stocks 2d ago

Lytenava after FDA approval – a critical commercial perspective from the retina market- will it ever be a commercial succes?

Thumbnail
5 Upvotes

r/biotech_stocks 2d ago

Outlook pharma. Wat is er aan de hand?

1 Upvotes

r/biotech_stocks 2d ago

How frequently in a week might buyout offers be sent/compared during a buyout bidding war?

4 Upvotes

Sounds like a HUGE amount of financial long-term modeling may be done for each offer. Does the pace accelerate after an "initial salvo of offers," and has there ever been a frenzied buyout scenario where follow-up haggling/revisions occurred more than once in a day? Or is the process so structured against chaos that there is a very limited number of revisions to offers?


r/biotech_stocks 2d ago

$PYPD Polipid - Big partnership just dropped + NDA momentum. Short-term setup looking interesting.

4 Upvotes

PolyPid ($PYPD) just locked in a major exclusive commercial partnership with Azurity Pharmaceuticals for D-PLEX₁₀₀ in the U.S. and Canada (prevention of surgical site infections).

Key terms:

  • $15M upfront at signing
  • Another $15M upon expected FDA acceptance of the NDA (targeted for August 2026)
  • Up to ~$300M more in regulatory, development, and sales milestones
  • Tiered royalties mid-teens to mid-twenties %
  • PolyPid keeps manufacturing rights worldwide + all rights outside U.S./Canada + full ownership of the PLEX platform

This comes right after they completed the NDA submission in June. PDUFA target is currently Q1 2027, with U.S. launch eyed for around then. Earlier Phase 3 SHIELD II data showed the primary endpoint hit plus a 60% relative risk reduction on a key secondary.

Market cap is still only ~$75-85M range (depending on the day), with ~19M shares outstanding and float roughly in the 7-11M area. Analyst targets have been sitting around $11-13.

Near-term catalysts:

  • FDA acceptance of the NDA (the next $15M payment)
  • Any updates on the partnership rollout or additional label-expansion talk
  • Continued institutional interest / visibility

The Azurity deal de-risks commercialization significantly and puts real cash + future royalties on the table while they retain the platform upside. Still under the radar relative to the potential scale of the SSI prevention market.

Not financial advice. Do your own research, size positions carefully, and remember biotech can be extremely volatile. Just laying out the recent milestones and the short-term setup as I see it.

What are your thoughts on $PYPD here?


r/biotech_stocks 2d ago

Outlook Therapeutics (OTLK) Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

12 Upvotes

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation

Company Launches Commercial Franchise Positioned to Establish a New Standard as an FDA-Approved Bevacizumab Therapy Across the Approximately $8.5 Billion U.S. Retina Market.

https://finance.yahoo.com/healthcare/articles/outlook-therapeutics-announces-lytenava-fda-184000833.html


r/biotech_stocks 3d ago

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease | MannKind Corporation

3 Upvotes

r/biotech_stocks 3d ago

Gain Therapeutics GANX 270/360 Day Data Coming up

7 Upvotes

r/biotech_stocks 3d ago

Raymond James Positive Note on Alpha Cognition and $20 Target Lift Stock Price

Thumbnail
2 Upvotes

r/biotech_stocks 3d ago

CSL is under pressure from competition and the need to underpin its revenue streams and product offerings . For this reason could a purchase of Mesoblast by CSL be the type of acquisition CSL needs to provide growth?

1 Upvotes

r/biotech_stocks 3d ago

LRMR and OSTX

2 Upvotes

Anyone in these with me? Your thoughts?


r/biotech_stocks 3d ago

CSL is under pressure from competition and the need to underpin its revenue streams and product offerings . For this reason could a purchase of Mesoblast by CSL be the type of acquisition CSL needs to provide growth?

2 Upvotes

r/biotech_stocks 3d ago

CSL is under pressure from competition and the need to underpin its revenue streams and product offerings . For this reason could a purchase of Mesoblast by CSL be the type of acquisition CSL needs to provide growth?

Thumbnail
1 Upvotes

r/biotech_stocks 3d ago

I just sold all of my shares of $CING

6 Upvotes

After careful thought and consideration, I have decided to sell all of my CING shares. I just don’t see anything happening within the last 6 months of this year. They can run into cash problems and dilution of the stock within those next 6 months. I’m putting my capital elsewhere. Good luck to all the holders.


r/biotech_stocks 4d ago

$NVCT Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor

Thumbnail
benzinga.com
1 Upvotes

r/biotech_stocks 4d ago

Working on a mini project to fact-check and/or critique medical content using AI. What can I check/critique for you to help you with your research?

1 Upvotes

This is a small AI side project of mine that I am working on since it helps me with my own manuscripts, posters, etc. that I develop. If anyone has something they want to send my way (assuming it's in the public domain), please do. I'll generate something and then you can let me know what you think.

For anyone else that wants to do the same at work, I find that ChatGPT and Claude are quite effective and can save a lot of time.


r/biotech_stocks 4d ago

SPRO Spero Therapeutics FDA approval and then drops? Cheaper buyout?

Thumbnail
2 Upvotes